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magnitude of clinical benefit when used in patients earlier 
in the mCRPC setting.
Conclusions Sipuleucel-T stimulates long-lived immune 
responses that translate into long-term clinical benefit. The 
treatment course (three infusions at weeks 0, 2, and 4) is 
associated with manageable side effects. Short-term mark-
ers of future benefit would be clinically useful, and infor-
mation on effective treatment combinations or sequences is 
awaited.
Patient summary Sipuleucel-T treatment directs the 
patient’s own immune system to target and remove pros-
tate cancer cells and increases life expectancy. Patients 
whose cancer is less advanced generally have a more 
‘active’ immune system and may benefit the most from this 
treatment.
Keywords Immunotherapy · Metastatic castration-
resistant prostate cancer · Prostate cancer · Sipuleucel-T
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Abstract 
Context Prostate cancer remains highly prevalent and 
has a poor clinical outcome once metastatic. Sipuleucel-T 
is an autologous cellular immunotherapy approved for the 
treatment of metastatic castration-resistant prostate cancer 
(mCRPC). Sipuleucel-T treatment extends survival but is 
independent of traditional short-term markers of treatment 
response observed with chemotherapy and contemporary 
hormonal treatments. Therefore, it is essential that clini-
cians understand the mechanism of action of sipuleucel-T 
and how this can translate in the clinic.
Objective This article aims to summarize the cur-
rent knowledge of sipuleucel-T therapy and its effects in 
mCRPC.
Evidence acquisition Relevant publications describ-
ing sipuleucel-T clinical data and information relating to 
immunotherapies were identified.
Evidence synthesis Treatment with sipuleucel-T extends 
survival, with side effects being usually mild or moderate 
and manageable within the outpatient setting. The long-
term immune responses generated by sipuleucel-T corre-
late with a survival benefit. Sipuleucel-T shows a greater 
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Introduction
Approximately 400,000 men are diagnosed with prostate 
cancer in Europe each year, equating to almost a quarter of 
all male cancers [1]. Around 90,000 prostate cancer-related 
deaths occur annually in Europe, giving it the third highest 
mortality rate after lung and colon cancers [1], and in the 
USA, it is surpassed only by lung cancer [2].
Men with localized prostate cancer are generally treated 
with active surveillance, brachytherapy, surgery, or radio-
therapy with or without androgen deprivation therapy 
(ADT), depending on the individual prognosis [3]. Patients 
treated with ADT alone for metastatic disease usually 
respond well, but ultimately biochemical relapse and dis-
ease progression may occur. Castration-resistant prostate 
cancer (CRPC) may be suspected in patients with new 
symptoms, rising prostate-specific antigen (PSA) levels, 
or other new evidence of disease while being treated with 
ADT [4]. Treatment options for patients who progress to 
metastatic CRPC (mCRPC) have evolved dramatically over 
recent years and include the following: immunotherapy 
with sipuleucel-T [5, 6]; androgen biosynthesis inhibition 
with abiraterone acetate and prednisone [7]; androgen sign-
aling inhibition with enzalutamide [8]; chemotherapy in 
combination with steroids, such as docetaxel or cabazitaxel 
and prednisone; and bone-targeted agents including the 
radioisotope radium-223 dichloride [9]. Additional immu-
notherapies are under investigation for mCRPC, such as the 
cytotoxic T-lymphocyte antigen 4 inhibitor ipilimumab, for 
which phase III trial results were recently published [10].
Sipuleucel-T is an autologous cellular immunotherapy 
that is indicated for the treatment of asymptomatic or mini-
mally symptomatic mCRPC [11]. In April 2010, sipuleu-
cel-T became the first US Food and Drug Administration 
(FDA)-approved immunotherapy following the demonstra-
tion of significant overall survival (OS) improvement in 
patients with primarily asymptomatic or minimally symp-
tomatic mCRPC [5, 12, 13]. Sipuleucel-T was also recently 
approved by the European Medicines Agency (EMA) for 
the treatment of asymptomatic or minimally symptomatic 
metastatic (non-visceral) CRPC in male adults in whom 
chemotherapy is not yet clinically indicated [14]. A Euro-
pean study of sipuleucel-T is ongoing across centers in 
Vienna, Nijmegen, London, and Paris, with the product 
manufactured in Maastricht (The Netherlands) using the 
standard methodology (see section ‘Manufacture of sip-
uleucel-T’). In addition, sipuleucel-T is being explored in 
earlier and later settings, and the initial findings have been 
positive [15]. In clinical trials, sipuleucel-T was well tol-
erated and had manageable side effects [16]; the major-
ity of adverse events were mild or moderate and could be 
managed in an outpatient setting. In order to appreciate 
the long-term clinical benefits of sipuleucel-T treatment, it 
is important to understand how these are derived from its 
mode of action.
Evidence acquisition
Relevant publications presenting data on sipuleucel-T treat-
ment, predominantly from key clinical trials, were identi-
fied. Additional articles commenting on these data, and on 
the results achieved with sipuleucel-T and other immuno-
therapies, were also included.
Evidence synthesis
Data and other information from the identified publications 
were collated and are presented below.
Manufacture of sipuleucel‑T
Sipuleucel-T uses the patient’s own cells to stimulate an 
immune response against prostatic acid phosphatase (PAP), 
which is an appropriate target as it is expressed almost 
exclusively by prostate cells. The potential for inappropri-
ate immune reactions is limited because sipuleucel-T is 
composed of the patient’s own cells.
The first step in the manufacture of sipuleucel-T is to isolate 
the patient’s peripheral blood mononuclear cells (PBMCs), 
including antigen-presenting cells (APCs) such as dendritic 
cells, macrophages, and B cells, using leukapheresis (Fig. 1). 
These cells are then cultured in vitro for 36–44 h with a fusion 
protein, PA2024, composed of recombinant PAP fused to 
granulocyte–macrophage colony-stimulating factor (GM-
CSF), a cytokine that stimulates APCs. Stimulating APCs ex 
vivo is thought to be an effective approach for initiating an 
immune response away from the potentially immunosuppres-
sive effects of the prostate tumor. Ex vivo PA2024-activated 
APCs have been shown to process and display fragments 
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of the PAP moiety on the cell surface [18]. The sipuleucel-
T product is then reinfused back into the patient, where the 
activated APCs stimulate an immune response against PAP 
and consequently against the cancerous prostatic cells. The 
potency of sipuleucel-T may be assessed by the upregulation 
of cluster of differentiation 54 (CD54) on APCs (measured as 
an increase in the ratio of the average number of molecules 
of CD54 on APCs pre- vs post-culture with PA2024) [18]. 
Cumulative APC activation and APC number correlated with 
OS in an analysis of three randomized controlled phase III 
trials [19]. Thus, current sipuleucel-T manufacture requires 
that the product contains a minimum of 50 million autolo-
gous CD54+ cells [11]. The complete treatment involves three 
cycles 2 weeks apart (weeks 0, 2, and 4), with each cycle 
comprising fresh leukapheresis, cell isolation and culture with 
PA2024, and reinfusion. The sipuleucel-T product contains T 
cells, APCs, natural killer cells, and B cells, and the cellular 
composition does not change between treatment weeks nor 
between pre-culture compared with the final product [19].
Engagement of the immune system during manufacture 
of sipuleucel‑T
Significant levels of in vitro APC activation, measured by 
CD54 upregulation, are induced during co-culture of the 
patient’s cells with PA2024 [18–20]. Greater increases in 
APC activation are seen during the second and third (weeks 
2 and 4) in vitro co-cultures compared with the first (week 
0). This response profile is akin to that generated by tra-
ditional vaccines—a prime-boost effect is observed after 
the first dose when administering sequential vaccinations. 
Significant positive correlations were observed between OS 
and cumulative (across the three infusions) post-culture in 
vitro APC activation, APC count, and total nucleated cell 
(TNC) count, which remained after adjusting for baseline 
PSA and lactate dehydrogenase (LDH) levels (Fig. 2) [19].
There is evidence to suggest that antigen-specific T and B 
cell responses developed following the first sipuleucel-T infu-
sion, and that these were re-stimulated during the subsequent 
co-cultures. Cytokines that are associated with T cell activation 
were detected in culture medium from the second and third in 
vitro co-cultures, and included interleukin (IL)-2, IL-4, IL-5, 
IL-6, IL-10, IL-13, IL-17, interferon gamma (IFNγ), IFNγ-
inducible protein 10, and tumor necrosis factor alpha [19, 20]. 
In addition, levels of the T cell activation markers CD134 and 
CD137 were increased on CD4+ and CD8+ T cells after cul-
ture with PA2024, and there was evidence of B cell matura-
tion and activation [20]. Furthermore, PA2024-specific T cell 
‘recall’ responses, measured by antigen-specific proliferation 
and IFNγ production, could be detected in pre-culture cells 
from the second and particularly the third leukapheresis [19, 
20]. This suggests that functional T cell responses were gener-
ated in the body after the first infusion and were subsequently 
boosted after the second infusion. Each of these findings rein-
forces the hypothesis that sipuleucel-T treatment induces an 
immunologic ‘prime-boost’ response.
Post‑treatment immune responses with sipuleucel‑T 
and correlation with OS
T cell responses, such as proliferation and IFNγ production 
in response to stimulation with either PA2024 or PAP, could 
be detected in PBMCs from the majority of patients treated 
with sipuleucel-T [19]. This indicates that the treatment 
Fig. 1  Sipuleucel-T immunotherapy and proposed mode of action. 
Leukocytes are harvested from the patient by leukapheresis and sent 
for processing, in which monocytes are enriched by density-gradient 
centrifugation. The monocytes are incubated with the PA2024 fusion 
protein of PAP and GM-CSF. PA2024 is taken up by immature APCs, 
such as DCs, and enhances their maturation. The resulting ‘product’ 
is returned to the clinic and administered intravenously to the patient. 
Theoretically, the transfused APCs will present PAP-derived peptides 
to the host immune system in vivo, activating CD4+ and CD8+ T 
cells and initiating adaptive immune responses. Adapted by permis-
sion from Macmillan Publishers Ltd: Nature Reviews Immunology 
2010, Vol. 10, Drake CG, Prostate cancer as a model for tumor immu-
notherapy, pp. 580–93, copyright 2010 [17]. APC antigen-presenting 
cell. CD cluster of differentiation. DC dendritic cell. GM-CSF granu-
locyte–macrophage colony-stimulating factor. MHC major histocom-
patability complex. PA2024 fusion protein of PAP and GM-CSF. PAP 
prostatic acid phosphatase. TCR T cell receptor
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generated prostate antigen-specific immune responses. Pre-
liminary evidence also suggests that this peripheral blood 
immune response has a direct effect within the prostate, as 
demonstrated by an increased number of leukocytes around 
the tumor site [21]. In the neoadjuvant setting, patients with 
non-metastatic prostate cancer who were treated with sip-
uleucel-T displayed a ≥3-fold increase in mean cells/area at 
the tumor interface for total T cells, CD4+ helper T cells, and 
CD8+ cytotoxic T cells, compared with pre-treatment biopsy 
or with non-interface areas of benign or malignant tissue [21].
Robust post-treatment antibody responses specific to 
PA2024 and PAP have also been detected in the major-
ity of patients treated with sipuleucel-T, but not in con-
trol patients [19]. In the majority of sipuleucel-T-treated 
patients, antigen-specific antibodies remained present 
at detectable levels in serum for at least 26 weeks. The 
majority of the antibody responses were initially immuno-
globulin M, with immunoglobulin G antibodies emerging 
2–4 weeks after the last infusion. This isotype switching is 
consistent with vaccine-induced immunologic memory. In 
addition, anti-tetanus antibody responses were unchanged 
after sipuleucel-T treatment, indicating that bystander 
immune responses were not generated.
Antibodies in the systemic circulation may, theoreti-
cally, reach many tissues, potentially allowing the destruc-
tion of malignant cells throughout the body and resulting 
in long-term, widespread immunosurveillance. There is 
also potential for the immune system to recognize addi-
tional ‘nontarget’ cancer antigens through a process known 
as epitope spreading, to enable it to better identify and 
remove cancerous cells. Epitope spreading is particularly 
noted in the development of long-term antibody responses. 
This antigen cascade event may explain why OS 
significantly correlated with an antibody response against 
PA2024 [hazard ratio (HR) 0.42; p < 0.001] [19] and high-
lights the importance of humoral immunity in this context. 
OS also significantly correlated with the development of 
either a functional T cell response (above) or a humoral 
response (Fig. 3).
Overall, these data support the concept that engagement of 
key immune cell types (APCs, T, and B cells) during sipuleucel-
T treatment contributes to the OS benefit. However, there are 
additional data to suggest that engagement of ‘less prominent’ 
immune cell types could also be important. Approximately 
30 % of the patients in three phase III trials experienced a tran-
sient increase in peripheral blood eosinophil counts from week 
6 to week 14, directly after completion of sipuleucel-T treatment 
[22]. Eosinophils are often considered to be rare, cytotoxic cells 
that are only relevant in parasitic infections and asthma [23]. 
However, there is increasing evidence that eosinophils may be 
involved in the generation of sipuleucel-T antitumor immune 
responses [23]. This may be through interactions with T cells 
(recruitment and polarization or direct antitumor activity), B cells 
(antibody responses), or dendritic cells (activation/recruitment). 
Indeed, the transient, elevated eosinophil counts in patients 
receiving sipuleucel-T correlated with OS, prostate cancer-spe-
cific survival, and antigen-specific humoral responses [22].
Optimizing the use of sipuleucel‑T
Surrogate markers for OS
Unlike traditional chemotherapy, sipuleucel-T treatment is 
associated with a long-term OS benefit but not a reduction 
in time to objective disease progression (defined by at least 
one of the following criteria: an increase in at least 50 % in 
Fig. 2  Significant correlation between OS and cumulative a APC 
activation, b APC (CD54+ cell) count, and c TNC count (product 
parameters) following co-culture of cells with PA2024. Kaplan–
Meier survival plots are shown for each product parameter above ver-
sus below the median value; p values from analysis of each parameter 
as a continuous measure were calculated with and without adjust-
ment for baseline PSA and LDH levels. Reproduced from Cancer 
Immunology Immunotherapy 2013, Vol. 62, Sheikh NA, Petrylak D, 
Kantoff PW, et al., Sipuleucel-T immune parameters correlate with 
survival: an analysis of the randomized phase 3 clinical trials in men 
with castration-resistant prostate cancer, pp. 137–47. Copyright 2012, 
the Author(s) [19]. APC antigen-presenting cell, CD cluster of differ-
entiation, GM-CSF granulocyte-macrophage colony-stimulating fac-
tor, LDH lactate dehydrogenase, OS overall survival, PA2024 fusion 
protein of PAP and GM-CSF, PAP prostatic acid phosphatase, PSA 
prostate-specific antigen, TNC total nucleated cell
659Cancer Immunol Immunother (2015) 64:655–663 
1 3
the sum of the products of diameters for index lesions; the 
new appearance or unequivocal progression of non-index 
lesions; at least two new lesions on bone scanning; and/or 
a new pathologic fracture or spinal cord compression [5]). 
The same phenomenon has been noted with other immu-
notherapies. For example, treatment with PSA-TRICOM 
did not increase time to prostate cancer progression but 
achieved a significant improvement in 3-year OS {30 % vs. 
17 %; HR 0.56 [95 % confidence interval (CI), 0.37–0.85]} 
and median survival (25.1 vs. 16.6 months; p = 0.0061) 
versus control [6]. Similarly, in melanoma, ipilimumab 
treatment did not result in an improvement in median pro-
gression-free survival (PFS), but a significant extension of 
median OS was achieved (10.1 months in ipilimumab arms) 
compared with active control (6.4 months; p < 0.001 and 
p = 0.003, respectively) [24]. Therefore, traditional short-
term indicators of long-term survival benefits may not be 
appropriate with sipuleucel-T or other immunotherapies.
This seeming discrepancy may relate to the immu-
nomodulatory mode of action. Antigen-specific immune 
responses take time to generate, and therefore tumor 
shrinkage may be delayed compared with traditional thera-
pies (Fig. 4a) [25, 26]. It is also likely that an initial inflam-
matory influx of leukocytes into a tumor could lead to an 
initial, nonpathogenic increase in size, followed by a sub-
sequent, long-term antitumor response [25]. Thus, immu-
nologic memory could enable the body to continue to fight 
the tumor and slow its growth long after the immunothera-
peutic treatment has been completed [25, 26]. Further-
more, theoretically, long-term immunosurveillance could 
act throughout the body as well as within the prostate, 
and could potentially target metastatic cells, limiting their 
spread.
Fig. 3  Significant correlation between OS and immune respond-
ers or non-responders to sipuleucel-T treatment as determined by 
a response to either PA2024 or PAP, b response to PA2024, and c 
response to PAP, in at least one of the three immune response assays 
(antibodies, IFNγ-production, and proliferation). Kaplan–Meier sur-
vival plots are shown; p values from analysis of each parameter were 
calculated with and without adjustment for baseline PSA and LDH 
levels. Reproduced from Cancer Immunology Immunotherapy 2013, 
Vol. 62, Sheikh NA, Petrylak D, Kantoff PW, et al., Sipuleucel-T 
immune parameters correlate with survival: an analysis of the rand-
omized phase 3 clinical trials in men with castration-resistant pros-
tate cancer, pp. 137–47. Copyright 2012, the Author(s) [19]. GM-CSF 
granulocyte–macrophage colony-stimulating factor. IFNγ interferon 
gamma. LDH lactate dehydrogenase. OS overall survival. PA2024 
fusion protein of PAP and GM-CSF. PAP prostatic acid phosphatase. 
PSA prostate-specific antigen
Fig. 4  Proposed kinetics of immunomodulatory treatments. In a, 
immunotherapy is compared with cytotoxic chemotherapy. Tumor 
burden is shown if a no therapy is initiated, b chemotherapy is initi-
ated, or c immunomodulatory therapy is initiated. For patients who 
received immunotherapy, there may be little if any reduction in tumor 
size, and therefore little or no increase in time to progression, but an 
increase in OS. Dagger denotes time of death. In b, early versus late 
initiation of immunomodulatory therapy is explored. The survival 
benefit may be increased if immunomodulatory treatment is initiated 
earlier in disease progression (d) but may be decreased in patients 
with a large tumor burden (e). Reproduced from Schlom J. Therapeu-
tic cancer vaccines: current status and moving forward. J Natl Cancer 
Inst 2012;104(8):599–613, by permission of Oxford University Press 
[31]. OS overall survival
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Clinically, short-term markers of future benefit from 
immunotherapies would be very useful. In this regard, the 
transient increase in eosinophil counts in peripheral blood, 
noted from week 6 to week 14, may play a role given that 
this correlates with OS [22]. Eosinophil counts are rou-
tinely measured in this context; therefore, after further 
investigation and validation, elevated eosinophil counts 
could be a potentially useful surrogate marker.
Sipuleucel-T’s position within the treatment paradigm
Sipuleucel-T was evaluated in three randomized phase III 
studies [D9901: NCT00005947; D9902A: NCT01133704; 
and Immunotherapy for Prostate Adenocarcinoma Treat-
ment (IMPACT; D9902B): NCT00065442] of patients 
with asymptomatic or minimally symptomatic mCRPC, 
and consistent improvements in OS, compared with pla-
cebo, were observed across the studies [5, 12, 13, 16]. 
FDA and EMA approval of sipuleucel-T was based primar-
ily on the pivotal IMPACT study which demonstrated that 
sipuleucel-T was associated with improved median survival 
(4.1 months; 25.8 vs. 21.7 months in the sipuleucel-T and 
control arms, respectively), increased 3-year survival (31.7 
vs. 23.0 % in the sipuleucel-T and control arms, respec-
tively) and a 22.5 % reduction in risk of death (HR 0.78; 
95 % CI 0.61–0.98; p = 0.03). Although there were more 
adverse events in the sipuleucel-T group, compared with 
the placebo group, these events were primarily related to 
leukapheresis and infusion. Most events were mild to mod-
erate (typically chills, fever, fatigue, nausea, and/or head-
ache), occurred within 1 day of infusion, and resolved 
within 1–2 days, with very few patients (0.9 %) prema-
turely discontinuing sipuleucel-T therapy [5].
A commentary by Huber et al. [27] questioned the trial 
design and the validity of the results from the IMPACT 
study. The following concerns were raised: (1) unexpected 
interactions between patient age and survival, (2) older 
patients in the placebo group appeared to have shorter OS 
than might be expected based on the results of other stud-
ies, and (3) the number of cells harvested and reinfused to 
the patients. Three subsequent publications rebutted these 
concerns [28–30] and presented clear explanations as to 
why, due to comparisons between asymmetric and small 
subgroups, and a lack of evaluable data, the article by 
Huber et al. was misleading. Moreover, independent bod-
ies, such as the FDA and the Center for Medicare and Med-
icaid Services, also found the issues raised by Huber et al. 
not to be credible, supporting the published rebuttals. In 
summary, the claims made by Huber et al. were considered 
to be unfounded, a view supported overwhelmingly by the 
regulatory bodies and key thought leaders in the field.
Further to the above-summarized clinical trial data sup-
porting improvements in OS of patients with asymptomatic 
or minimally symptomatic mCRPC treated with sipuleucel-
T, several lines of evidence support sipuleucel-T use earlier 
within the treatment paradigm. Treating patients earlier in 
the disease course would allow more time for the immune 
response to develop and would theoretically allow patients 
to benefit most from the long-term OS advantage (Fig. 4b). 
In addition, several factors associated with improved survival 
following sipuleucel-T treatment, such as APC activation 
and transient elevations in eosinophil counts, are greater or 
more frequent in patients with characteristics of earlier-stage 
disease [15, 22, 27]. Indeed, the cumulative fold increase in 
APC activation, as measured by CD54 upregulation, was 
significantly greater in patients with earlier-stage disease; 
the fold increase was 35.5 in neoadjuvant patients, 28.7 in 
asymptomatic or minimally symptomatic mCRPC patients, 
and 21.8 in mCRPC patients (p < 0.0001; Joncheere-Terpstra 
test) [31]. In addition, patients with characteristics of ear-
lier-stage disease may show greater OS [32], a greater time 
to first opioid analgesic use, and a trend toward a delay in 
time to disease-related pain after sipuleucel-T treatment than 
those with later-stage disease characteristics [33].
Future directions with sipuleucel‑T in the management 
of prostate cancer
Several ongoing and planned studies will investigate fur-
ther the optimal role for sipuleucel-T in the management of 
prostate cancer (Table 1). These trials are addressing sev-
eral aspects of sipuleucel-T therapy, such as use in earlier 
treatment settings (neoadjuvant, hormone sensitive, and 
non-metastatic) and the combination of sipuleucel-T with 
other agents (chemotherapy, radiotherapy, ADT, abiraterone 
acetate, and immunotherapeutics). Use of sipuleucel-T ear-
lier in the prostate cancer paradigm may have considerable 
benefits to patients, since these patients are generally able 
to mount more robust immune responses [15, 22, 27], and 
there may be more time for the sustained, durable immune 
responses to exert their clinical benefit [32–34]. Preliminary 
data on the use of sipuleucel-T before, concurrently with, 
or after additional anticancer therapies are also encourag-
ing. In the IMPACT trial, sipuleucel-T use was associated 
with increased survival versus placebo irrespective of previ-
ous chemotherapy or docetaxel use, radiotherapy, prostatec-
tomy, orchiectomy, castration, or combined androgen block-
ade [5]. In addition, a sipuleucel-T treatment effect was 
observed in patients with and without subsequent docetaxel 
use [35]. Preliminary data from the P11-3 study suggest that 
treatment with abiraterone acetate and prednisone does not 
substantially affect the leukocyte yield for most patients, 
and that sipuleucel-T can, therefore, be successfully manu-
factured alongside the use of these agents [36]. The poten-
tial effects of treatment sequencing on clinical outcomes 
are also under investigation. Preliminary interim results 
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from the phase II STAND trial (sequencing of sipuleucel-
T and ADT in men with non-metastatic prostate cancer; 
NCT01431391) show that combination treatment with ADT 
followed by sipuleucel-T may augment immune responses, 
which could potentially increase efficacy compared with 
either treatment alone  [37].
Conclusions
New, effective drugs with different mechanisms of action are 
essential for the treatment of prostate cancer, which remains 
highly prevalent and has both a high mortality rate and poor 
clinical outcome after biochemical relapse. Sipuleucel-T is 
a significant advance in the treatment of mCRPC and pro-
vides clinicians with an additional effective therapy. Treat-
ment with sipuleucel-T extends survival and is associated 
with easily manageable side effects, which are usually mild. 
Few patients prematurely discontinue sipuleucel-T therapy, 
and substantial long-term benefits can be achieved with just 
a 4-week treatment course. Research is ongoing to identify 
short-term markers of the long-term clinical benefits of sip-
uleucel-T treatment, to investigate its use in earlier disease 
settings, and in combination with other therapies.
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